MedTrace Logo

Azilsartan Circadian and Sleep Pressure

NCT01762501 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 957

Last updated 2015-12-28

Study results available
· View outcomes & findings →

Summary

To determine the efficacy of Azilsartan 20 mg versus Amlodipine 5 mg oral administration once per day for 8 weeks in patients with grade I or grade II essential hypertension.

Conditions

Interventions

DRUG

Azilsartan

Azilsartan 20mg/day

DRUG

Amlodipine

Amlodipine 5mg/day

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Sogo Rinsho Médéfi Co., Ltd.

    lead OTHER

Principal Investigators

  • Kazuo Kario · Chief Professor of Division of Cardiovascular Medicine, Jichi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01762501 on ClinicalTrials.gov